GI Windows Corp. scooped up $16.4 million in a series A-1 financing that included investment from Johnson & Johnson Innovation – JJDC Inc., Sonder Capital, GT Healthcare, JC Investco and an unnamed strategic investor. Also participating in the round were new investors Kennedy Trust and Coleman Trust. The funds are earmarked to advance the development and clinical trials of the company’s incisionless anastomosis technology.
The U.S. FDA has cleared the way for Abbott Laboratories sixth COVID-19 test, a near-patient, point-of-care antigen test that gives results in 15 minutes and can be run without laboratory equipment. The company has priced the Binaxnow COVID-19 Ag Card rapid test at $5 and is offering a complementary mobile app that allows people to display their test results when asked by organizations for verification.
Keeping you up to date on recent developments in diagnostics, including: A.I. tool promises faster, more accurate Alzheimer's diagnosis; Bioluminescent tool tracks DNA break repair; Mechanisms of retinopathy come into focus.
Regenerative therapies startup Jointechlabs Inc. has won the U.S. FDA’s nod for its MiniTC point-of-care fat tissue processing device. The 510(k)-cleared product is designed to extract microfat for use in grafts for a variety of indications, including medical aesthetics, plastic surgery, orthobiologics and wound healing.
Practice growth platform Patientpop scooped up $50 million in a series C financing led by HLM Venture Partners. The new funds are earmarked for telehealth and virtual care solutions to help private practices adapt to a rapidly health care environment and the challenges of seeing and treating patients during a global pandemic.
Informed Data Systems Inc. (IDS), doing business as One Drop, scooped up $98.7 million in new financing and commitments to accelerate the expansion of its digital health platform beyond diabetes. The company raised $34.7 million in a series C round led by Bayer AG, of Leverkusen, Germany. Bayer also committed $64 million in development fees and commercial milestones related to a 2019 licensing agreement to leverage the One Drop solution across multiple therapeutic areas.
The COVID-19 pandemic has had an enormous impact on elective and nonessential procedures, and with them the medical device companies they depend on, but early signs of recovery are encouraging, according to Raghav Tangri, of (DRG), which is part of Clarivate. That said, Tangri told BioWorld that while the second quarter is expected to be the most strongly impacted period this year, the speed of recovery will depend on a number of factors, including the possibility of a second wave of the coronavirus outbreak and how soon a vaccine is available.
The U.S. FDA has granted emergency use authorization (EUA) to Lumiradx UK Ltd. for its point-of-care SARS-CoV-2 antigen test, which aims to speed the diagnosis of people suspected of having the virus that causes COVID-19. The test detects antigen nucleocapsid protein from a nasal swab taken from symptomatic patients and delivers results in less than 12 minutes.
Keeping you up to date on recent developments in diagnostics, including: Antigen test detects spike proteins of SARS-CoV-2; Blood volume assessment study to use Daxor device; Gaining insights into loss of function.
The U.S. FDA has greenlighted two new modules for Siemens Healthineers’ AI-Rad Companion platform, giving radiologists new artificial intelligence (AI) tools to assist in interpreting magnetic resonance imaging (MRI) studies of the brain and prostate. The AI-Rad Companion Brain MR for Morphometry Analysis and AI-Rad Companion Prostate MR for Biopsy Support join earlier intelligent software modules for Chest CT.
